Photo by nci from unsplash
e21038Background: While most ALK+ NSCLC patients (pts) initially respond to crizotinib, resistance ultimately develops. The identification of fusion partners and mutations in ALK has led to the dev... Click to show full abstract
e21038Background: While most ALK+ NSCLC patients (pts) initially respond to crizotinib, resistance ultimately develops. The identification of fusion partners and mutations in ALK has led to the dev...
Keywords:
molecular predictors;
alk;
long term;
nsclc patients;
term response;
predictors long
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!